Shareholder Class Action Filed On Behalf Of Investors In Elan Corporation, plc Against S.A.C. Capital Advisors, LP And Affiliates By The Law Firm Of Kessler Topaz Meltzer & Check, LLP

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130107:nPnPH38497

RADNOR, Pa., Jan. 7, 2013 /PRNewswire/ -- The following statement was issued
today by the law firm of Kessler Topaz Meltzer & Check, LLP:

Notice is hereby given that a class action lawsuit was filed in the United
States District Court for the Southern District of New York on behalf of
purchasers the American Depositary Receipts ("ADRs") ofElan Corporation, plc
(NYSE: ELN) ("Elan" or the "Company"), between July 21, 2008 and July 29,
2008, inclusive (the "Class Period"). If you are a member of this class, you
may view a copy of the Complaint or join this class action online at
http://www.ktmc.com/cases.

The Complaint alleges that S.A.C. Capital Advisors, L.P. ("SAC"), CR Intrinsic
Investors, LLC ("CR Intrinsic"), a wholly-owned subsidiary of SAC, and other
related parties, including SAC's founder and chief executive officer, Steven A.
Cohen, violated the Securities Exchange Act of 1934 by selling over 15 million
Elan ADRs and purchasing over $1 million worth of Elan put options. These
transactions resulted in the defendants receiving over $220 million in illegal
profits and avoided losses by trading on material non-public information.
Specifically, the defendants traded ahead of a negative public announcement
involving the clinical trial results for bapineuzumab ("bapi"), an Alzheimer's
drug being jointly developed by Elan and Wyeth.

According to the Complaint, a portfolio manager at CR Intrinsic, Mathew
Martoma, obtained inside information from the medical doctor who chaired bapi's
Phase II clinical trial safety monitoring committee, Sidney Gilman. The
Complaint further alleges that after Martoma received such material non-public
information from Gilman regarding the drug's clinical trial results, he shared
this information with defendant Cohen, who then, with Martoma, caused SAC and CR
Intrinsic to liquidate their combined holdings in Elan ADRs, worth over $365
million, and take substantial short positions, eventually selling over $500
million in Elan securities in just over one week.

When the full results of bapi's Phase II clinical trial were publicly disclosed
after the market closed on July 29, 2008, Elan's ADRs dropped sharply in value,
declining 41.8% from their closing price prior to the public disclosure.
According to the Complaint, by liquidating their long positions and selling
short in advance of the disclosure of the disappointing clinical trial results,
this illegal scheme allowed the defendants to collectively reap illicit profits
and avoid losses of over $220 million.

Defendant Martoma is presently the subject of a criminal prosecution in
connection with his role in this scheme. Defendant Gilman has settled civil
charges brought by the Securities and Exchange Commission, has agreed to
disgorge over $200,000, and has entered into a non-prosecution agreement with
the U.S. Attorney's Office for his role.

Members of the class may, not later than February 19, 2013, move the Court to
serve as a lead plaintiff of the class. A lead plaintiff is a representative
party that acts on behalf of other class members in directing the litigation.
In order to be appointed lead plaintiff, the Court must determine that the class
member's claim is typical of the claims of other class members, and that the
class member will adequately represent the class. Your ability to share in any
recovery is not, however, affected by the decision of whether or not to serve as
a lead plaintiff. Any member of the purported class may move the court to serve
as lead plaintiff through counsel of their choice, or may choose to do nothing
and remain an absent class member.

If you wish to discuss this action or have any questions concerning this notice
or your rights or interests with respect to these matters, please contact
Kessler Topaz Meltzer & Check, LLP (Darren J. Check, Esq. or D. Seamus
Kaskela, Esq.) toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at
info@ktmc.com. For additional information about this lawsuit, or to join the
class action online, please visit http://www.ktmc.com/cases.

Plaintiff seeks to recover damages on behalf of class members and is represented
by the law firm of Kessler Topaz Meltzer & Check, LLP, which prosecutes class
actions in both state and federal courts throughout the country. Kessler Topaz
Meltzer & Check is a driving force behind corporate governance reform, and has
recovered billions of dollars on behalf of institutional and individual
investors from the United States and around the world. For more information
about Kessler Topaz Meltzer & Check, or for additional information about
participating in this action, please visit www.ktmc.com.

CONTACT: Kessler Topaz Meltzer & Check, LLP
Darren J. Check, Esq.
D. Seamus Kaskela, Esq.
280 King of Prussia Road
Radnor, PA 19087
1-888-299-7706 (toll free) or 1-610-667-7706
Or by e-mail at info@ktmc.com

SOURCE Kessler Topaz Meltzer & Check, LLP